Capivasertib+abiraterone was associated with more symptomatic AEs but did not impact HRQoL in patients with PTEN-deficient ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...

Disitamab vedotin has shown antitumor activity in HER2-expressing subgroups with pretreated, locally advanced unresectable or metastatic urothelial cancer.

In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.

Consuming more plant-based foods following prostate cancer diagnosis was associated with improved sexual function, among other QOL domains.

Investigators evaluated the long-term neurological, neurocognitive, social, and quality of life outcomes associated with posterior fossa syndrome among survivors of medulloblastoma.

Reduced-dose ARSI therapy in non-metastatic castration-resistant prostate cancer has similar efficacy and safety as the full dose.

In this population-based analysis, researchers aimed to assess whether menopausal hormone therapy increases the risk of all-cause mortality.

For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.